CVS Health shares tumbled in early Friday trading after the healthcare and retail pharmacy giant ousted its CEO and pared back profit forecasts amid a broader industry slump.
CVS Health (CVS) , along with health insurance rivals UnitedHealth (UNH) , Humana (HUM) and Cigna (CI) , is facing a surge in medical costs tied to the aging demographics of its customer base plus a pullback in reimbursements from Medicare and Medicaid under new strictures from the Biden administration.
💰💸 Don’t miss the move: SIGN UP for TheStreet’s FREE Daily newsletter 💸💰
Earlier this week, UnitedHealth posted a big jump in its medical-cost ratio, a gauge of the amount the group is collecting from premiums against the payouts it needs to make to customers, and issued a muted 2025 profit forecast.
Longer-term concerns about profit margins in the sector are tied to the U.S. Centers for Medicare and Medicaid Services' decision last spring to cap Medicare Advantage payments by an average of 3.7% next year.
Analysts were looking for an increase of around 4.7%, based on CMS's January proposal of 3.7%, and followed by an increase of around 1.22% each year between 2019 and 2024.
The payments, which reimburse insurers for treatments of U.S. patients over age 65, will be effectively lower than current levels when adjusted for costs and inflation.
Related: Elevance Health stock tumbles on Medicaid, Medicare changes
CVS has felt similar cost and reimbursement pressures. It slashed its full-year profit forecast in May and posted a near 6 percentage-point surge in the benefit-expense ratio at Aetna, its health insurance unit.
To arrest that rise and boost sales and profits at its retail pharmacy division, CVS said Friday that it has replaced CEO Karen Lynch, who was appointed in 2021, with CVS Caremark President David Joyner.
CVS: 'Time is right' for new CEO
"The board believes this is the right time to make a change, and we are confident that David is the right person to lead our company for the benefit of all stakeholders, including customers, employees, patients, and shareholders," CVS Chairman Roger Farah said in a statement.
Related: Humana hit by troubling Medicare Advantage change
"To build on our position of strength, we believe David and his deep understanding of our integrated business can help us more directly address the challenges our industry faces, more rapidly advance the operational improvements our company requires, and fully realize the value we can uniquely create," he added.
More Health Care:
- Humana hit by troubling Medicare Advantage change
- These new money and health findings might surprise you
- Many Americans fear Medicare won’t be there when they need it
The group also lowered its outlook for third-quarter earnings, which are expected on Nov. 6, to between $1.05 and $1.10 per share, well south of Wall Street's $1.70 forecast, and withdrew its profit forecast for the full year, citing "continued elevated medical cost pressures in the Health Care Benefits segment."
CVS also said its medical-benefit ratio would likely rise by at least 10 percentage points when compared to the third quarter of 2023 to around 95.2%
CVS shares were last marked 8.2% lower in early Thursday trading to change hands at $58.48 each, a move that would extend the stock's year-to-date decline to around 30%.
Related: Veteran fund manager sees world of pain coming for stocks
